Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Macular Degeneration Research
Completed Award

Dr. Sally Temple

Sally Temple, Ph.D.

Regenerative Research Foundation
Rensselaer, NY

Title: The role of Sox2 in AMD
Non-Technical Title: The role of a critical eye development gene, SOX2, in Age-related Macular Degeneration

Duration: April 1, 2008 - March 31, 2010
Award Type: Standard
Award Amount: $100,000

Summary:

This study will determine whether Sox2 is expressed in the retina of patients with AMD and the consequence of varying its concentration. This research will contribute to understanding the progression of AMD, and help identify ways to slow or even halt its advance.

Details:

The researchers have discovered that a gene critical for producing the normal eye is turned on abnormally in the retina of AMD patients. This gene, Sox2, controls other genes, including one that is already associated with AMD, alphaB-crystallin. Abnormal expression of Sox2 may lead to abnormal expression of other genes such as alphaB-crystallin, and this sequence may contribute to AMD. The Sox2 gene expressed in AMD is an unusual variant, and it might be an excellent target for AMD treatment. This study will determine whether Sox2 is expressed in the retina of patients with AMD, and whether it is the Sox2 variant found in early, preliminary studies. Sox2 gene expression will also be turned off and on in cell cultures to test the effect on alphaB-crystallin protein. This research will contribute to understanding the progression of AMD, and help identify ways to slow or even halt its advance. I have been involved in stem cell biology for nervous system diseases for nearly two decades. Five years ago, my mother was diagnosed with Age-related Macular Degeneration (AMD), a degenerative disease of the retina. This personal experience has committed me to apply my skills in stem cell and molecular biology to work on AMD, which is so prevalent amongst our growing elderly population.